Overview. Retatrutide (development code LY3437943) is a synthetic peptide developed by Eli Lilly and Company, in active clinical development. It is not an approved pharmaceutical product; the material in NuePharma’s catalog is supplied strictly for research use only, and is not the pharmaceutical product used in Eli Lilly’s clinical trials.
Molecule / class. Retatrutide is described in the scientific and clinical-trial literature as a triple receptor agonist peptide.
Mechanism under investigation. It is designed to simultaneously activate three receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. A dual agonist activates two of these mechanisms; a single-receptor agonist activates one. Researchers are studying combined activity across all three because each receptor is independently linked to different aspects of glucose and energy metabolism, and combining them is hypothesized to produce effects distinct from targeting any one receptor alone — see the terminology hub for what “receptor” and “agonist” mean generally.
Why the pathway is researched. GLP-1 receptor activity is the mechanism behind an established, widely studied drug class; GIP and glucagon receptor activity are being studied for potential additive or complementary metabolic effects. This is an active area of pharmaceutical research, not a settled question.
Human research. As of the most recent publicly reported results, retatrutide has completed a major Phase 3 trial (TRIUMPH-1, registered on ClinicalTrials.gov) studying its effect in adults with obesity or overweight, and is in Phase 3 study for several additional conditions, including type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, and cardiovascular and kidney outcomes. Reported topline results describe substantial average weight loss at the highest studied dose over roughly 80 weeks, though full peer-reviewed publication and regulatory review are what ultimately establish an approved use, not a topline announcement.
Regulatory status. Retatrutide is not FDA-approved. It remains an investigational compound, meaning its safety and effectiveness for any use are still under formal review, not yet officially established the way an approved medicine’s are. NuePharma’s RUO material is not equivalent to, and is not derived from, the material used in Eli Lilly’s clinical trials.
What remains unknown. Long-term safety and effectiveness data, the final approved indication and dosing (if approval occurs), and how findings from controlled trial populations generalize more broadly are all still being established through the ongoing trial program.
NuePharma product information. NuePharma’s Retatrutide listing is 15 mg per vial, supplied lyophilized, for research use only.